Shares of Structure Therapeutics surged 6.1% to $42.84 in early trading on September 9, clawing back ground after a punishing 14.7% drop the session before — a volatile two-day stretch driven entirely by how Wall Street is digesting new clinical results for the company's oral obesity drugs. Structure Therapeutics' Obesity Pill Matches Novo Nordisk's Oral Wegovy on Weight Loss — But Is a $3.4 Billion Biotech Ready to Take On Pharma Giants?
Shares of Structure Therapeutics rebounded 6.1% to $42.84 on September 9, partially recovering from a sharp 14.7% selloff the prior session that appeared driven not by flawed data but by a broader healthcare sector rotation. Jefferies noted GPCR shares were potentially dragged down by a wider pullback across the obesity sector, with no fundamental issues emerging from either the trial readout or the public call. The company's dual data drop — its strongest clinical catalyst yet — deserves a closer look.
• The Weight-Loss Numbers Stack Up Against the Biggest Names
Structure's lead oral obesity pill produced up to 16.2% mean body-weight reduction at 72 weeks with no observed plateau, and fewer than 5% of participants quit due to side effects. Critically, BMO Capital Markets called this efficacy "in line" with Novo Nordisk's Wegovy pill and said it "bests" Eli Lilly's recently launched Foundayo,
which showed 12.4% weight loss at 72 weeks. For a clinical-stage company with a $3.4 billion market cap competing against two of the world's largest drugmakers, matching their results in a mid-stage trial is a meaningful validation.
• The Data Came With a Big Asterisk
Participants were only titrated to the highest 180 mg dose after Week 60, meaning they had relatively limited exposure to the top dose by Week 72. In plain terms, patients spent most of the trial on lower doses and still hit 16.2% — suggesting the ceiling could be higher. That's a compelling narrative for the Phase 3 program, but it also means the headline number is extrapolated, not settled.
• A Second Drug Adds Strategic Depth
CEO Raymond Stevens called ACCG-2671 "the first reported clinical data for an oral small molecule amylin receptor agonist," a separate weight-loss mechanism from the GLP-1 class that dominates today's market. The company plans a combination trial of both drugs in Q4 2026, which could differentiate it from rivals relying on a single mechanism. Investors buying GPCR are essentially betting on two shots on goal, not one.
• A Long Cash Runway, but a Longer Wait for Revenue
Structure reported $1.3 billion in cash as of June 30, enough to fund operations through 2028. But Phase 3 topline data aren't expected until the second half of 2028, meaning at least two years of zero revenue lie ahead. Analysts' average 12-month price target sits at $104.77, more than double the current price — a gap that reflects enormous optimism but also enormous execution risk. At $42.84, the stock trades 55% below its January all-time high of $93.79, leaving investors to decide whether the discount prices in the risk or the opportunity.